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Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative disease characterized by an accumulation of fibroblasts
and myofibroblasts in the alveolar wall. Even though the pathogenesis of this fatal disorder remains unclear, transforming
growth factor-b (TGF-b)-induced differentiation and proliferation of myofibroblasts is recognized as a primary event. The
molecular pathways involved in TGF-b signalling are generally Smad-dependent yet Smad-independent pathways, including
phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), have been recently proposed. In this research we established ex-
vivo cultures of human lung fibroblasts and we investigated the role of the PI3K/Akt pathway in two critical stages of the
fibrotic process induced by TGF-b: fibroblast proliferation and differentiation into myofibroblasts. Here we show that the
pan-inhibitor of PI3Ks LY294002 is able to abrogate the TGF-b-induced increase in cell proliferation, in a- smooth muscle
actin expression and in collagen production besides inhibiting Akt phosphorylation, thus demonstrating the centrality of
the PI3K/Akt pathway in lung fibroblast proliferation and differentiation. Moreover, for the first time we show that PI3K
p110d and p110c are functionally expressed in human lung fibroblasts, in addition to the ubiquitously expressed p110a and
b. Finally, results obtained with both selective inhibitors and gene knocking-down experiments demonstrate a major role of
p110c and p110a in both TGF-b-induced fibroblast proliferation and differentiation. This finding suggests that specific PI3K
isoforms can be pharmacological targets in IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a interstitial lung
disease characterized by aberrant matrix deposition and
destruction of the normal lung architecture [1]. Survival of
IPF patients is poor, with a 5-year survival rate of only 20% [2].
IPF has historically been treated with corticosteroids and/or
cytotoxic agents such as prednisone without any evidence-based
benefit. Given the inefficacy of conventional therapies, novel
strategies are required for the management of IPF as well as a
better understanding of the molecular mechanisms underlying
the pathogenesis and progression of this disease. A determinant
role in IPF is played by myofibroblasts, as these cells,
characterized by a–smooth muscle actin (a-SMA) fibres, have
a contractile phenotype and abundantly synthesize collagen and
ECM proteins [3]. Myofibroblasts may be derived by activa-
tion/proliferation of resident lung fibroblasts, epithelial-mesen-
chymal differentiation, or recruitment of circulating fibroblastic
stem cells (fibrocytes). Transforming growth factor-b1( T G F - b1)
is known to induce the differentiation of human lung fibroblasts
into myofibroblasts [4,5]. However, the molecular pathways
involved in TGF-b-induced myofibroblast transformation have
only been partially identified and Smad-dependent as well as
independent pathways, including PI3K, have been proposed [6–
8]. PI3K is a signal transduction enzyme that catalyzes the
phosphorylation of phosphatidylinositol (4,5)-biphosphate to
form phosphatidylinositol (3,4,5)-triphosphate in response to the
activation of receptor tyrosine kinases, G protein coupled
receptors/cytokine receptors and activated Ras. PI3K signalling
has been implicated in the control of a wide range of cellular
activities such as proliferation, survival, adhesion, differentia-
tion, cytoskeletal organization, etc. [9,10]. PI3Ks have been
divided into three classes according to their structure and lipid
substrate specificity. The most extensively investigated are the
class I PI3Ks that act on PI-(4,5)-bisphosphate (PIP2) to produce
PI-(3,4,5)-triphosphate (PIP3). Prototypical class I PI3K is a
dimeric enzyme, consisting of catalytic and regulatory subunits.
The catalytic subunit occurs in four isoforms, designated as
p110a,p 1 1 0 b,p 1 1 0 c and p110d, which are sub-grouped into
Class IA (p110a,p 1 1 0 b and p110d)a n dI B( p 1 1 0 c). These
isoforms have been demonstrated to have both overlapping and
unique roles in physiology and disease states. To date, both
genetic manipulation and pharmacological inhibitors have been
utilized to understand the roles of individual PI3K isoforms and
distinct kinase functions as well as kinase-independent functions
have been revealed.
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e24663In this research we investigated the role of the PI3K pathway in
the TGF-b-induced proliferation of ex-vivo human lung fibroblasts
and their differentiation into myofibroblasts. Moreover, by using
selective inhibitors of class I PI3K p110 isoforms as well as specific
gene suppression by small interfering RNA (siRNA) we further




The Italian and institutional policies of humane care have been
abided by conscientiously and our study was approved by the
Azienda Ospedaliera ‘Garibaldi, S.Luigi-Curro `, Ascoli-Tomaselli’
ethical committee. Written informed consent was obtained from
all participants involved in the study.
PI3K inhibitors
LY294002 was from Sigma, AS-252424 and TGX-221 were
from Enzo Life Sciences AG (Lausen, Switzerland), IC87114 from
BioVision (Mountain View, CA, USA), YM-024 was kindly
provided by Prof. Shaun P. Jackson, Australian Centre for Blood
Diseases, Monash University, Melbourne, Australia). TGF-b was
from Chemicon. All others reagents were from Sigma.
Cell culture and treatments
Lung fibroblast cells were derived from histologically normal
areas of surgical lung specimens from patients undergoing
resective surgery for benign or malignant tumors. Primary lines
were established by using an outgrowth from explants according
to the method by Jordana and coworkers [11] as previously
described [12]. In all the experiments, cell lines were used at a
passage earlier than the height. Prior to treatment, cells were
Figure 1. Effects of PI3Ks pan-inhibitor LY294002 on TGF-b-induced proliferation of human lung fibroblasts and their
differentiation into myofibroblasts. Ex vivo human lung fibroblasts were cultured in vitro and all cell lines (from five different donors) were
used at a passage earlier than eight. Prior to treatment, cells were incubated for 24 hrs in serum-free RPMI medium, then left resting or treated with
LY294002, at indicated concentrations, one hour before subsequent TGF-b stimulation (10 ng/ml) in the absence or presence of LY294002. Afterward,
cells were incubated for 48 hrs in serum-free medium and then harvested. A) Representative western blot analysis of phosphorylated (Ser
473) Akt and
pertinent graph with the pAKT/a-tubulin ratios of five separate experiments. B) Results of cell counting by optical microscopy (grey columns) and
WST-1 cell proliferation assay (black columns) were represented as % increase over control (untreated cells, assumed as 100%). C) Flow-cytometry
analysis of a-SMA expression: mean values (6 sd) of Mean Fluorescence Intensity (MFI) are indicated. Plots of one representative experiment are
shown in FigureS1. D) Total collagen levels, measured by the Sircol Soluble Collagen Assay, were reported as % increase over control. Statistical
significance across treatment groups was determined using the one-way ANOVA. A P value ,0.05, which indicates a statistically significant difference
among relevant groups, is designated with an asterisk.
doi:10.1371/journal.pone.0024663.g001
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resting or treated with various PI3K inhibitors one hour before
subsequent TGF-b stimulation (10 ng/ml, Chemicon) in the
absence or presence of PI3K inhibitors. Afterward, cells were
incubated for 24 or 48 hrs in serum-free medium. All of the
phenotypic and functional parameters were then evaluated. The
cytotoxicity of all substances was evaluated by the LDH
cytotoxicity detection kit (Roche). Transfections with commer-
cially available siRNA specific for PI3K p110 isoforms a and c as
well as with a negative control (Qiagen, Flexi Tube Gene
Solution SI00605843, SI02665369 and AllStars Negative Con-
trol, respectively) were performed in serum free for 24 hours by
using siPORT
TM Amine Transfection Agent (Ambion, Inc.)
following manufacturer’s protocol. Afterward transfection medi-
um was replaced and cells were stimulated or not with TGF-b for
24 hours in 2% FBS medium.
Cell proliferation
Cell numbers were determined by counting cells on a
hemocytometer (Burker chamber) after trypan blue staining. A
mean of four fields was used to calculate the average number of
cells. Cell proliferation was also evaluated by using the cell
proliferation WST-1 kit (Roche, Basel, Switzerland). Briefly,
after the specified treatment, cells were exposed to WST-1 for
1h o u r a t 3 7 uC. The formation of WST-1 formazan was
spectrophotometrically monitored using a reference wavelength
of 480 nm.
Collagen production
TGF-b–stimulated fibroblasts or resting cells, cultured in the
absence or presence of inhibitors, were scraped into a lysis
buffer..Total soluble collagen was measured by the Sircol Soluble
Collagen Assay (Biocolor, Newtownabbey, United Kingdom). The
collagen-dye complex was precipitated by centrifuging at
10,0006g for 10 minutes. The precipitated complex was resus-
pended in 1 ml alkali reagent. The solution obtained was finally
placed in a 96-well flat-bottomed plate and evaluated in a plate
reader (absorbance, 540 nm).
Flow-cytometry analysis of a-SMA expression
The cells were washed, fixed with paraformaldehyde (PFA) 2%,
and permeabilized with Triton 16(Sigma-Aldrich). The cells were
then incubated for 60 minutes with a-SMA-ab (1:200; DAKO,
Glostrup, Denmark), anti-hTGF-b1 (1:200; R&D Systems,
Minneapolis, Minn). Subsequently, the cells were washed once
with PBS/BSA 1% and incubated with Goat F(ab9) 2 Fragment
Anti-Mouse IgG (H1L)-FITC (Beckman Coulter, Milano, Italy).
Samples were analyzed by using a Coulter Epics Elite ESP flow
cytometer (Coulter Corp, Miami, Fla).
RNA extraction and RT-PCR
Total RNA from cells was extracted by using TRIZOL reagent
(Invitrogen Inc., Paisley, UK), quantified by specrophotometric
analysis with a BIO-photometer (Eppendorf, Germany) and
treated with DNAse (Invitrogen, UK). The generation of cDNA
Figure 2. Expression of PI3Kclass IA p110d and class IB p110c in human ex-vivo lung fibroblasts. A) RT-PCR products of PI3K p110d run
in 2% agarose gel (upper line) and western blot analysis of proteins from four different fibroblast cell lines (medium line). The protein loading control
was a-tubulin (bottom line). A commercially available RT-PCR kit and a monoclonal rabbit anti human PI3K p110d (1:500) were used as detailed in the
Mat and Met section. B) RT-PCR products of PI3K p110c run in 2% agarose gel and western blot analysis of proteins from the same fibroblast cell lines
indicated in panel A. A commercially available RT-PCR kit and a monoclonal mouse anti human PI3Kp110c (1:500) were used.
doi:10.1371/journal.pone.0024663.g002
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TM II Reverse
Transcriptase (RT, Invitrogen, UK) and random hexamer primers
(Invitrogen, UK), according to the manufacturer’s instructions.
Quantitative real-time PCR of cDNAs was performed using the
IQ SYBR Green Supermix (QIAGEN, Germany) in conjunction
with commercially available GAPDH, PI3K p110c (QIAGEN)
and PI3K p110d assays (Applied Biosystems), according to the
manufacturer’s instructions. PCR amplicons were also run in 2%
agarose gel and visualized by sybr-safe DNA stain (Invitrogen).
Western blot analysis
Resting, treated and/or transfected cells were lysed in a solution
of 10 mM EDTA, 1% Triton x-100, 1 mM PMSF (phenylmethyl-
sulfonylfluoride) and 15 ml/ml Protease Inhibitor Cocktail (all
from Sigma-Aldrich Corp.). Protein concentrations were deter-
mined by the Bradford method. Samples were then diluted in
sample buffer and boiled for 5 min. Electrophoresis was
performed on a 12% SDS-PAGE gel (40 mA/h) using 60 mgo f
proteins/lane. After electrophoresis, the proteins were transferred
onto a nitrocellulose membrane (Hybond ECL, Amersham
Biosciences Europe GmbH, Milan, Italy) for 2 hrs at room
temperature with a transblot semidry transfer cell. After BSA
blocking, the membranes were incubated overnight at 4uC with:
monoclonal mouse anti- ha-SMA Ab (1:500, Dako Cytomation,
Denmark), or rabbit anti hp(Ser
473)-Akt (1:200; Cell Signaling
Technology, Beverly, MA), monoclonal rabbit anti hPI3K p110a
(1:500, Cell Signalling), monoclonal rabbit anti h-PI3K p110b
(1:500, Abcam), monoclonal mouse anti hPI3K p110c (1:500,
Abcam), monoclonal rabbit anti hPI3K p110d (1:500, Abcam),
monoclonal mouse anti hGAPDH (1: 200, Chemicon) . Mem-
branes were then thoroughly washed and incubated with
horseradish peroxidase-conjugated anti-mouse or anti-rabbit
secondary antibodies (1:5,000; Santa Cruz Biotechnology, Inc.,
California, USA) . Specific bands were visualized using the
Quantum Dot detection system (Invitrogen).
Statistical analysis
Statistical significance across treatment groups was determined
by using the one-way ANOVA with Tukey’s multiple-comparison
with Statgraphic Centurion XV software (StatPoint Technologies
Figure 3. Effects of selective PI3K p110a inhibition. Ex vivo human lung fibroblasts (from three different donors) were cultured and treated
with YM-024 following the protocol indicated in Figure 1. A) Representative western blot analysis of phosphorylated (Ser
473) Akt and pertinent graph
with pAKT/a-tubulin ratios of three separate experiments. B) Results of cell counting by optical microscopy (grey columns) and WST-1 cell
proliferation assay (black columns). C) Flow-cytometry analysis of a-SMA expression: MFI mean values (6 sd) of three separate experiments are
indicated. Plots of one representative experiment are shown in FigureS2. D) Total collagen levels were reported as % increase over control. Statistical
significance across treatment groups was determined using the one-way ANOVA. A P value ,0.05, which indicates a statistically significant difference
among relevant groups, is designated with an asterisk.
doi:10.1371/journal.pone.0024663.g003
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statistically significant difference, is designated with a single
asterisk.
Results
Role of PI3K/Akt pathway in TGF-b-induced proliferation
and differentiation into myofibroblast
TGF-b is a potent paracrine mediator of myofibroblast
differentiation and contributes to the development of pulmonary
fibrosis following the expansion of lung myofibroblasts. Therefore,
when ex-vivo human lung fibroblasts were treated with TGF-b
(10 ng/ml) in serum free conditions for 48 hours, as expected, cells
exhibited a faster proliferation rate and differentiated toward a
myofibroblast phenotype characterized by a-SMA expression and
collagen production, as shown in Figure 1. Moreover, as a
consequence of TGF-b treatment, levels of pAKT increased
(Figure 1A). Since all such effects were abrogated by co-treatment
with LY294002, the broad spectrum inhibitor of the PI3K
signalling pathway (Figure 1A–D), it is evident that PI3K/AKT
activation induced by TGF-b plays a central role in both the
proliferation of human lung fibroblasts as well as their differen-
tiation into myofibroblasts.
Expression of class I PI3Ks in human ex-vivo lung
fibroblasts
LY294002 is a pan inhibitor of all four class I PI3Ks, yet it has
been generally recognized that only p110a and p110b are
ubiquitously expressed whereas p110d and p110c are restricted
to haematopoietic cell lineages. Therefore, we also wanted to
ascertain the expression of p110d and p110c in human lung
fibroblasts. We performed RT-PCR as well as western blot
analysis. As shown in Figure 2, the results demonstrate that both
p110d and p110c are expressed at mRNA and protein levels in
human lung fibroblasts.
Effects of pharmacological inhibition of specific class I
PI3K p110 isoforms
Since in several models, including lung disease, a unique
biological activity has been shown for different class I PI3Kp110
Figure 4. Effects of selective PI3K p110b inhibition. Ex vivo human lung fibroblasts (from three different donors) were cultured, and treated
with TGX-221 following the protocol indicated in Figure 1. A) Representative western blot analysis of phosphorylated (Ser
473) Akt and pertinent graph
with pAKT/a-tubulin ratios of three separate experiments. B) Results of cell counting by optical microscopy (grey columns) and WST-1 cell
proliferation assay (black columns) were represented as % increase over control. C) Flow-cytometry analysis of a-SMA expression: MFI mean values
(6 sd) of three separate experiments are indicated. Plots of one representative experiment are shown in FigureS3. D) Total collagen levels, were
reported as % increase over control. Statistical significance across treatment groups was determined using the one-way ANOVA. A P value ,0.05,
which indicates a statistically significant difference among relevant groups, is designated with an asterisk.
doi:10.1371/journal.pone.0024663.g004
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lung fibroblast proliferation and differentiation into the myofi-
broblasts induced by TGF-b. Specific inhibitors of class IA PI3K
isoforms (YM-024, TGX-221 and IC87114 for p110a,p 1 1 0 b
and p110d, respectively) and class IB (AS-252424 for p110c)w e r e
used to dissect the specific role of each isoform. Concentrations
around each IC50 in a range of non-overlapping effects, were
utilized according to literature data [13–16]. All the drugs were
checked for cytotoxicity by an LDH test and no significant
toxicity was observed for any inhibitor in the used range (data not
shown).
As shown in Figure 3, blocking p110a activity by treatment
with YM-024 was able to dose-dependently suppress the TGF-b–
induced increase in both pAkt and a-SMA expression levels
(panel A and C, respectively). Moreover, significant inhibition of
cell proliferation and collagen production was achieved at high
doses (panel B and D, respectively). By contrast, treatment with
the specific p110b inhibitor TGX-221, on one hand was able to
significantly inhibit TGF-b–induced Akt activation (Figure 4A)
and B, respectively) yet on the other hand it was only able in part
to reduce cell proliferation rates, at high doses, and it did not
produce any significant variation of either a-SMA expression or
collagen deposition (Figure 4, panel C and D, respectively).
Differently, suppression of p110d activity by IC87114 that dose-
dependently prevented Akt phosphorylation was also able to
inhibit a-SMA expression and collagen deposition, yet without
any dose-dependence, besides marginally affecting the prolifera-
tion rate, as shown in Figure 5. Finally, the effects of class IB
p110c suppression by AS-252424 are demonstrated in Figure 6
which shows a blockade of Akt activation paralleled by a dose-
dependent decrease in cell proliferation rate as well as a-SMA
expression and collagen deposition. The extent of these effects,
less so than in the case of LY294002 but comparable to that
observed in the case of p110a inhibition, therefore suggests a
complementary role of these isoforms. Interestingly, by using AS-
252424 at a concentration $5 mmolar, probably affecting also
p110a, the TGF-b-induced effects were completely suppressed
(data not shown).
Figure 5. Effects of selective PI3K p110d inhibition. Ex vivo human lung fibroblasts (from three different donors) were cultured, and treated
with IC-87114 following the protocol indicated in Figure 1. A) Representative western blot analysis of phosphorylated (Ser
473) Akt and pertinent
graphic with pAKT/a-tubulin ratios of three separate experiments. B) Results of cell counting by optical microscopy (grey columns) and WST-1 cell
proliferation assay (black columns) were represented as % increase over control. C) Flow-cytometry analysis of a-SMA expression: MFI mean values
(6 sd) of three separate experiments are indicated. Plots of one representative experiment are shown in FigureS4. D) Total collagen levels were
reported as % increase over control. Statistical significance across treatment groups was determined using the one-way ANOVA. A P value ,0.05,
which indicates a statistically significant difference among relevant groups, is designated with an asterisk.
doi:10.1371/journal.pone.0024663.g005
PI3K in Fibroblasts Transformation/Proliferation
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e24663Effects of selective gene suppression of p110 isoforms a
and c
In order to confirm the results obtained by pharmacological
inhibition we performed a specific gene suppression by transfecting
cells with small interfering RNAs (siRNAs) specifically targeting
p110a and p110c RNAs as well as with a negative control with no
homology to any known mammalian gene.
Figures 7 and 8 show the data of one representative experiment
out of three separate transfections (in three different cell lines) with
siRNA, for p110a or p110c respectively, which obtained
comparable results. As indicated by western blot analysis shown
in panels A, transfections with siRNAs in unstimulated cells
produced slight variations of PI3K p110 isoforms’ protein levels.
This finding indicates that PI3K p110 isoforms a and c are very
stable proteins (with low turnover) whose levels were only slightly
affected by siRNA transfections. However, these variations caused
a small but significant effect on cell proliferation (panels B).
Moreover, selective gene knocking produced a 29–67% specific
inhibition of TGF-b-induced increase in p110a or p110c
expression (including some newly synthesized proteins) as well as
an equivalent significant suppression of TGF-b-induced increase
in cell proliferation, a-SMA and collagen expression (panels C and
D). On the contrary, AKT-Ser
473 phophorylation induced by
TGF-b was only marginally affected (panels A, bottom).
Furthermore, it is noteworthy that, on one hand, the negative
control inhibited the increase in gene expression of both PI3K
p110 isoforms as well as in cell proliferation and fibrosis markers
induced by TGF-b stimulation (the most plausible reason for this is
that an interaction between siRNAs/siPort and TGF-b, and/or its
receptors, occurred and lowered the effects of the latter); on the
other hand, specific siRNAs produced significantly higher
inhibitory effects compared to the negative control’s.
Discussion
The molecular pathogenetic mechanisms of IPF remain unclear
and few if any efficacious therapies are available for this fatal
disease. Therefore, large gaps in knowledge remain and novel
antifibrotic drugs are urgently needed for its treatment. In a recent
paper, by inhibiting Akt activation in human lung fibroblasts we
provided evidence that phosphorylation of this serine/threonine
Figure 6. Effects of selective PI3K p110c inhibition. Ex vivo human lung fibroblasts (from three different donors) were cultured, and treated
with AS-2524224 following the protocol indicated in Figure 1. A) Representative western blot analysis of phosphorylated (Ser
473) Akt and pertinent
graph with pAKT/a-tubulin ratios of three separate experiments. B) Results of cell counting by optical microscopy (grey columns) and WST-1 cell
proliferation assay (black columns) were represented as % increase over control. C) Flow-cytometry analysis of a-SMA expression: MFI mean values
(6 sd) of three separate experiments are indicated. Plots of one representative experiment are shown in FigureS5. D) Total collagen levels, were
reported as % increase over control. Statistical significance across treatment groups was determined using the one-way ANOVA. A P value ,0.05,
which indicates a statistically significant difference among relevant groups, is designated with an asterisk.
doi:10.1371/journal.pone.0024663.g006
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ation into myofibroblasts which play an essential role in fibrotic
disease [12]. Moreover, it has been shown that fibroblasts isolated
from IPF patients display pathological activation of Akt [17]. In
this study we investigated the role of the upstream PI3Ks and we
demonstrate that the TGF-b-induced proliferation of ex-vivo
human lung fibroblasts as well as their differentiation into
myofibroblasts depends on class I PI3Ks being activated. In fact,
cell treatment with LY294002 (the pan-inhibitor of class I PI3Ks)
was able to completely abrogate the TGF-b-induced proliferative
effect as well as a-SMA expression and collagen production.
Furthermore, transfections with selective siRNAs for PI3K p110a
and p110c produced similar results. This finding agrees with
previously reported observations on murine cell lines [6] and with
a recent study demonstrating that PI3K/Akt plays an important
role in the fibrogenesis of human lung fibroblasts induced by
bleomycin by up-regulating cell growth and collagen expression
[18]. Moreover, we show that in addition to ubiquitously
expressed p110a and b, human lung fibroblasts also express
p110d and c thus suggesting that their expression is not restrained
within the haematopoietic system, in accordance with previously
published data. In particular, several observations have demon-
strated that p110c is functionally expressed in mouse cardiofibro-
blasts (reviewed in [19]) as well as p110d being recently shown in
human peripheral lung tissue [20]. Furthermore, by using specific
pharmacological inhibitors we show a major role of PI3K p110c
and a in sustaining the TGF-b–induced increase in proliferation,
yet in a context of the functional redundancy of all class I isoforms.
Actually, all selective inhibitors were individually able (in varying
extents) to inhibit the proliferative effect but none alone emulated
the complete suppression of the pan-inhibitor LY294002. This
finding supports previously reported data on mouse embryonic
fibroblasts’ (MEFs) model [21] demonstrating the redundancy of
PI3K isoforms (at least for class IA PI3K, considering that MEFs
are not believed to express class IB p110c [22]) in sustaining cell
survival and proliferation hence suggesting that targeting all class I
PI3Ks is essential in producing the maximum inhibition of cell
proliferation. Moreover, selective gene knocking by siRNAs was
able to specifically inhibit about 30–65% of TGF-b-induced
p110a or p110c over-expression paralleled by a equivalent or
Figure 7. Effects of specific PI3K p110a gene suppression by siRNA. Ex vivo human lung fibroblasts (from three different donors) were kept
resting or transfected with small interfering RNAs (siRNAs) specifically targeting p110a (at the concentrations of 20 and 50 nM) or with negative
control (50 nM), for 24 hrs in serum-free RPMI medium, afterward they were kept resting or stimulated with TGF-b (10 ng/ml) for 24 hrs in 2% FBS
medium. A) Representative western blot analysis of p110a, phosphorylated (Ser
473) Akt and GAPDH expression. with means of p110a-/GAPDH and
pAKT/a-GAPDH ratios calculated in three separate experiments B) Results of cell counting by optical microscopy. Medians and standard deviations of
at least three separate counts in triplicate wells for three separate experiments are reported. C) Representative Western blot analysis of a-SMA
expression. and pertinent graph with means of a-SMA/GAPDH ratios calculated in three separate experiments. D) Total soluble collagen levels in one
ml of culture medium, measured by the Sircol Soluble Collagen Assay, were reported as micrograms for ml. Statistical significance across treatment
groups was determined using the one-way ANOVA. A P value ,0.05, which indicates a significant difference, is designated with an asterisk.
doi:10.1371/journal.pone.0024663.g007
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proliferation as well as in a–SMA and collagen expression,
therefore confirming a crucial role of both isoforms in sustaining
this process and their mutual interplay.
Furthermore, in TGF-b–induced fibrogenic effects, we show a
certain redundancy of class IA p110a and class IB p110c.
However, it is noteworthy that treatment with the specific p110c
inhibitor AS252424 at nanomolar concentrations much lower
than the IC50 of the other isoforms significantly prevented a-SMA
and collagen production induced by TGF-b whereas at concen-
trations $5 mM, probably also affecting p110c, it completely
abrogated these effects. Since a previously reported in vivo study
showed that oral administration of AS605240 significantly
prevented lung inflammation and reduced collagen deposition in
rats [23], our novel finding suggests that the effects of AS605240
(another p110c inhibitor) on bleomycin-induced pulmonary
fibrosis could be attributed not only to suppressing inflammatory
cell recruitment, as indicated in that paper, but also to a direct
anti-fibrotic effect on lung fibroblasts. Importantly, we also show
that the role of Akt downstream class I PI3Ks appears to be only
partial in TGF-b-induced proliferation and very marginal in
fibrogenic effects because, despite of the complete blockade of Akt
phosphorylation achieved by e.g. TGX-221, we observed slight
inhibition of the TGF-b-induced increase in proliferation and no
reduction at all of a-SMA expression or collagen production. This
finding was supported by results obtained with siRNA transfec-
tions. We showed that selective suppression of p110a/p110c gene
expression was able to significantly reduce the TGF-b-induced
fibroblast proliferation and fibrotic response without substantially
affecting AKT-Ser
473 phophorylation. Further investigation
should target other components of the PI3K signalling pathway.
Overall, our results suggest that class I PI3Ks might be
considered significant new targets for treating idiopathic pulmo-
nary fibrosis.
Figure 8. Effects of specific PI3K p110c gene suppression by siRNA. Ex vivo human lung fibroblasts (from three different donors) were kept
resting or transfected with small interfering RNAs (siRNAs) specifically targeting p110c (at the concentration of 20 and 50 nM) or with negative
control (50 nM), for 24 hrs in serum-free RPMI medium, afterward they were kept resting or stimulated with TGF-b (10 ng/ml) for 24 hrs in 2% FBS
medium. A) Representative western blot analysis of p110a, phosphorylated (Ser
473) Akt and GAPDH expression. with means of p110c-/GAPDH and
pAKT/a-GAPDH ratios calculated in three separate experiments B) Results of cell counting by optical microscopy. Medians and standard deviations of
at least three separate counts in triplicate wells for three separate experiments are reported. C) Representative Western blot analysis of a-SMA
expression and pertinent graph. Means of a-SMA/GAPDH ratios calculated in three separate experiments are indicated. D) Total soluble collagen
levels in one ml of culture medium, measured by the Sircol Soluble Collagen Assay, were reported as micrograms for ml. Statistical significance across
treatment groups was determined using the one-way ANOVA. A P value ,0.05, which indicates a significant difference, is designated with an asterisk.
doi:10.1371/journal.pone.0024663.g008
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Figure S1 Flow cytometry plots of one representative
experiment as described in Fig. 1. F=fibroblasts. Pertinent
Mean Fluorescence Intensity (MFI) is indicated below and
concentrations of LY294002 (LY) and TGF-b(TGF) are indicated
above each plot.
(TIF)
Figure S2 Flow cytometry plots of one representative
experiment as described in Fig. 3. F=fibroblasts. Pertinent
Mean Fluorescence Intensity (MFI) is indicated below and
concentrations of YM-024 (YM) and TGF-b (TGF) are indicated
above each plot.
(TIF)
Figure S3 Flow cytometry plots of one representative
experiment as described in Fig. 4. F=fibroblasts. Pertinent
Mean Fluorescence Intensity (MFI) is indicated below and
concentrations of TGX-221 (TGX) and TGF-b (TGF) are
indicated above each plot.
(TIF)
Figure S4 Flow cytometry plots of one representative
experiment as described in Fig. 5. F=fibroblasts. Pertinent
Mean Fluorescence Intensity (MFI) is indicated below and
concentrations of IC-87114 (IC) and TGF-b (TGF) are indicated
above each plot.
(TIF)
Figure S5 Flow cytometry plots of one representative
experiment as described in Fig. 6. F=fibroblasts. Pertinent
Mean Fluorescence Intensity (MFI) is indicated below and
concentrations of AS-2524224 (AS) and TGF-b (TGF) are
indicated above each plot.
(TIF)
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